Moderna, Pfizer and COVID-19

Moderna COVID Vaccine Technology Struck Down by PTAB
Patent Trial and Appeal Board (PTAB) docket entries indicate that the PTAB has invalidated all challenged claims of Moderna’s patents for its COVID-19 vaccine technology. The final written decisions remain sealed.
Pfizer convinces US Patent Office to cancel two Moderna COVID-19 vaccine patents
Pfizer and BioNTech won a round in their legal battle with Moderna over COVID-19 vaccine patents on Wednesday, convincing a U.S. Patent Office tribunal that two patents Moderna accused them of infringing were invalid.
Pfizer, BioNTech notch US win—and loss in Germany—amid high-stakes patent fight with Moderna
As part of a global web of patent litigation over COVID-19 vaccines and mRNA technology, Pfizer and its partner BioNTech traded blows this week with rival Moderna as dueling decisions came down in | Moderna sued Pfizer and BioNTech over three patents protecting its COVID-19 work back in 2022.
Pfizer and BioNTech COVID vaccine broke patent — German court
FRANKFURT - A German court found Wednesday that American pharmaceutical giant Pfizer and German firm BioNTech violated a patent to make their COVID-19 vaccine.Siding with Moderna, an American pharmaceutical firm that brought the case,
German court rules Pfizer, BioNTech violated Moderna's COVID-19 vaccine patent
A German court on Wednesday ruled that Pfizer and its partner BioNTech violated a COVID-19 vaccine patent held by Moderna .
Moderna wins patent lawsuit against BioNTech/Pfizer in German court
A German court ruled on Wednesday that BioNTech and Pfizer violated a Covid-19 patent held by rival Moderna. US-based Moderna had asserted claims for information and damages for infringement of its patent rights in the development of the Covid-19 vaccine.
Investor's Business Daily on MSN2d
Why Moderna Stock Has Surged 15% This Week Despite Mixed News
Moderna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open ...
Moderna Eyes 2027 Launch for Cancer Vaccine Developed With Merck
Moderna Inc. expects to launch a personalized cancer vaccine that it’s developing with Merck & Co. by 2027, one of its top ...
Moderna (NasdaqGS:MRNA) Rises 10% Despite US$1 Billion Revenue Drop Prediction
Moderna (NasdaqGS:MRNA) recently experienced a notable 10% price increase over the last week amidst significant legal and financial developments. Genevant Sciences and Arbutus Biopharma have expanded ...
Mutual of America Capital Management LLC Sells 1,087 Shares of Moderna, Inc. (NASDAQ:MRNA)
Mutual of America Capital Management LLC trimmed its position in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 2.6% during the ...
Moderna (MRNA) Stock Climbs as CEO and Director Make Strategic Insider Purchases
Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...
Moderna: Insider Buy Signal
Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...
MRNA Stock: Too High At $35?
Moderna (NASDAQ:MRNA) shares jumped 16% on Wednesday, March 5, following a favorable German court decision that determined ...
Yahoo Finance2d
Moderna, Inc. (MRNA)
Moderna stock has surged more than 20% this week after regulatory filings showed several executives bought shares on the open market. Moderna (NasdaqGS:MRNA) recently experienced a notable 10% ...
Why Moderna Stock Zoomed Nearly 16% Higher on Wednesday
A big legal victory across the Atlantic Ocean was the news propelling Moderna (NASDAQ: MRNA) stock to a significant price ...